Scholarlink

Purpose of Review <p>To discuss the biological mechanisms of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, the rationale for using CDK4/6 inhibitors in estrogen receptor-positive (ER+) and human epidermal growth factor receptor-2-negative (HER2-) breast cancer (BC), data from landmark phase III clinical trials that led to U.S. Food and Drug Administration (FDA) approval, and updates on recently published and ongoing clinical trials. Finally, we explore future directions of CDK4/6 inhibitors in the management of ER+ and HER2- BC.</p> Recent Findings <p>Based on landmark phase III clinical trials, CDK4/6 inhibitors have become essential to treat ER+ and HER2- BC.</p> Summary <p>New therapeutic strategies focused on CDK4/6 inhibitors are being evaluated and are expected to enter future pre-clinical and clinical trials, expanding the use of CDK4/6 inhibitors beyond currently FDA-approved indications. </p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Progress in Clinical Trials of CDK4/6 Inhibitors

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年10月22日

查看全文
  • Takae Mizukami,
  • Alberto J. Montero

摘要

Purpose of Review

To discuss the biological mechanisms of cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors, the rationale for using CDK4/6 inhibitors in estrogen receptor-positive (ER+) and human epidermal growth factor receptor-2-negative (HER2-) breast cancer (BC), data from landmark phase III clinical trials that led to U.S. Food and Drug Administration (FDA) approval, and updates on recently published and ongoing clinical trials. Finally, we explore future directions of CDK4/6 inhibitors in the management of ER+ and HER2- BC.

Recent Findings

Based on landmark phase III clinical trials, CDK4/6 inhibitors have become essential to treat ER+ and HER2- BC.

Summary

New therapeutic strategies focused on CDK4/6 inhibitors are being evaluated and are expected to enter future pre-clinical and clinical trials, expanding the use of CDK4/6 inhibitors beyond currently FDA-approved indications.